173604-87-0

Basic information

• Product Name: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl carbonate
• Synonyms: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methylp-nitrophenyl carbonate;Carbonic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl -ester;(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl carbonate
• CAS NO: 173604-87-0
• Molecular Formula: C₁₂H₉NO₈
• Molecular Weight: 295.2
• Mol File: 173604-87-0.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 434.798 °C at 760 mmHg
• Flash Point: 197.768 °C
• Appearance: /
• Density: 1.491
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl carbonate(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl carbonate(173604-87-0)
• EPA Substance Registry System: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl carbonate(173604-87-0)

Safety Data

• Hazardous Substances Data: 173604-87-0(Hazardous Substances Data)

Usage

General Description

(5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl carbonate is a complex organic compound with numerous atoms of carbon, hydrogen, nitrogen and oxygen in its structure. Its properties include its molecular formula (C13H11NO7), molecular weight (291.23 g/mol), exact mass, and monoisotopic mass. It also boasts a heavy atom count of 21, a complexity score of 578 and a covalently-bonded unit count of 1. (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-nitrophenyl carbonate belongs to the esters and derivatives class of chemicals. It's a synthetic compound that doesn't appear naturally, and it's mainly used in scientific research. It's not a consumer product nor is it a common ingredient in other chemical solutions.

InChI:InChI=1/C12H9NO8/c1-7-10(21-12(15)19-7)6-18-11(14)20-9-4-2-8(3-5-9)13(16)17/h2-5H,6H2,1H3

Upstream product

• 80841-78-7 4-chloromethyl-5-methyl-1,3-dioxol-2-one 
• 7693-46-1 4-Nitrophenyl chloroformate 
• 91526-18-0 4-hydroxymethyl-5-methyl-[1,3]dioxol-2-one 

Downstream Products

• 1055759-88-0 (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-[2-(hydroxyamino)-2-oxoethyl]-4-({4-[(2-methyl-4-quinolinyl)methoxy]benzoyl}amino)-1-piperidinecarboxylate 
• 1159589-10-2 n-butyl 4-[[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl oxycarbonylpiperidin-4-yl]-2-oxopiperazin-1-yl]acetyl]phenoxyacetate 
• 1220696-03-6 (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 3-(8-(1-(ethylsulfonyl)piperidin-4-ylamino)isoquinolin-6-yl)benzyl(methyl)carbamate 
• 1599486-22-2 C₃₈H₄₆N₂O₇S 
• 1333481-51-8 C₂₁H₁₈O₉S₂ 

Relevant articles and documents

PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER

There are provided compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, useful for inhibition or modulation of the activity of tyrosine kinases and treatment of disease states or conditions mediated by tyrosine kinases, including cancers. (I)

DERIVATIVES OF RELEBACTAM AND USES THEREOF

Derivatives of relebactam, therapeutic methods of using the derivatives of relebactam, particularly in combination with β-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The derivatives of relebactam are suitable for oral administration.

Coupling of an Acyl Migration Prodrug Strategy with Bio-activation to Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir

HIV-1 protease inhibitors (PIs), which include atazanavir (ATV, 1), remain important medicines to treat HIV-1 infection. However, they are characterized by poor oral bioavailability and a need for boosting with a pharmacokinetic enhancer, which results in additional drug-drug interactions that are sometimes difficult to manage. We investigated a chemo-activated, acyl migration-based prodrug design approach to improve the pharmacokinetic profile of 1 but failed to obtain improved oral bioavailability over dosing the parent drug in rats. This strategy was refined by conjugating the amine with a promoiety designed to undergo bio-activation, as a means of modulating the subsequent chemo-activation. This culminated in a lead prodrug that (1) yielded substantially better oral drug delivery of 1 when compared to the parent itself, the simple acyl migration-based prodrug, and the corresponding simple l-Val prodrug, (2) acted as a depot which resulted in a sustained release of the parent drug in vivo, and (3) offered the benefit of mitigating the pH-dependent absorption associated with 1, thereby potentially reducing the risk of decreased bioavailability with concurrent use of stomach-acid-reducing drugs.